![]() | Peter J KrauseYale School of Public Health, Department of Epidemiology of Microbial Diseases and Yale School of Medicine, New Haven, Connecticut, USA. | Department of Epidemiology of ... |
KOL Resume for Peter J Krause
Year | |
---|---|
2022 | Yale School of Public Health, Department of Epidemiology of Microbial Diseases and Yale School of Medicine, New Haven, Connecticut, USA. |
2021 | Yale School of Public Health and Yale School of Medicine, New Haven, CT, USA |
2020 | Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA Yale School of Public Health and Yale School of Medicine, New Haven Connecticut, United States |
2019 | Department of Epidemiology of Microbial Diseases, Yale School of Public Health and Departments of Medicine and Pediatrics, Yale School of Medicine, New Haven, CT, USA |
2018 | Department of Epidemiology of Microbial Diseases, Yale School of Public Health and Yale School of Medicine, New Haven, Connecticut Yale School of Medicine New Haven CT |
2017 | Yale School of Public Health and Yale School of Medicine, 60 College St., New Haven, CT 06520, USA |
2016 | Yale School of Public Health Division of Epidemiology of Microbial Diseases New Haven Connecticut |
2015 | Yale School of Medicine, New Haven, CT, USA |
2014 | Department of Epidemiology of Microbial Diseases Yale School of Public Health New Haven Connecticut |
2013 | Tufts University Cummings School of Veterinary Medicine North Grafton Massachusetts Department of Epidemiology and Public Health, Yale School of Public Health, New Haven, Connecticut. Yale School of Public Health and Yale School of Medicine, New Haven, Connecticut, United States of America Blood Systems Research Institute San Francisco California Emeritus, Walter Reed Army Institute of Research |
2012 | From the *Yale School of Public Health and Yale School of Medicine, New Haven, CT; and †Tufts Medical Center and Tufts University School of Medicine, Boston, MA. University of British Columbia, Vancouver, British Columbia, Canada (P.J. Keeling, A. Horak); Epidemiology and Public Health, Yale School of Medicine, New Haven, United States Yale School of Medicine, New Haven, Connecticut, USA (P.J. Krause, S. Bent, L. Rollend) |
2011 | Yale School of Public Health and Yale School of Medicine, New Haven, Connecticut, USA (D. Fish, P.J. Krause) Municipal Clinical Hospital No. 33, Yekaterinburg, Russia (N.A. Makhneva, M.G. Toporkova); Author affiliations: Central Research Institute of Epidemiology, Moscow, Russia (A.E. Platonov, L.S. Karan, N.M. Kolyasnikova, V.V. Maleev); |
2010 | Department of Epidemiology and Public Health, Yale School of Medicine, New Haven, Connecticut |
2009 | Connecticut Children's Medical Center, Hartford, Connecticut. e‐mail: Department of Epidemiology and Public Health Yale School of Medicine New Haven, CT |
2008 | University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030, USA Department of Epidemiology and Public Health, Yale School of Medicine, New Haven, Connecticut (Dr Krause), and the Division of Infectious Diseases, Department of Medicine, New York Medical College, Valhalla, New York (Dr Wormser). |
2007 | From the *Division of Infectious Diseases, Department of Medicine, University of Connecticut Health Center, Farmington, CT; and the †Divisions of Infectious Diseases and Cardiology, Department of Pediatrics, Connecticut Children’s Medical Center and the University of Connecticut School of Medicine, Hartford, CT. Department of Pediatrics, University of Connecticut School of Medicine and Connecticut Children's Medical Center, Hartford, Connecticut |
2006 | Department of Pediatrics, University of Connecticut School of Medicine and Connecticut Children's Medical Center, Hartford Pediatrics, University of Connecticut School of Medicine, Farmington, Connecticut 06030 |
2005 | Connecticut Children's Medical Center, Hartford, Connecticut, USA; |
2003 | Department of Pediatrics, University of Connecticut School of Medicine and Connecticut Children’s Medical Center, Hartford, Connecticut |
2002 | University of Connecticut School of Medicine and the Connecticut Children's Medical Center, Hartford, CT. Center for Microbial Pathogenesis |
2001 | Pediatrics, and Division of Infectious Disease, Connecticut Children's Medical Center, Hartford, CT |
2000 | Department of Pediatrics, Connecticut Children's Medical Center, Hartford, Connecticut 06106 University of Connecticut School of Medicine, Farmington, Connecticut |
1999 | Bacterial Zoonoses Branch, Division of Vector-Borne Infectious Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado; Department of Pediatrics and Department of Laboratory Medicine, University of Connecticut School of Medicine, Farmington, Connecticut; Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts; Department of Medicine, Brown University School of Medicine, Providence, Rhode Island The University of Connecticut, Farmington, Connecticut,2 and |
1998 | From the Department of Pediatrics, Division of Pediatric Infectious Diseases, Connecticut Children's Medical Center and University of Connecticut School of Medicine, Hartford (P.J.K., K.M., D.C., R.R.) |
1997 | Harvard School of Public Health, Boston, MA USA |
1996 | Department of Pediatrics, University of Connecticut School of Medicine, Farmington 06030, USA. |
1995 | Division of Pediatric Infectious Diseases, University of Connecticut, Farmington (P.J.K.) |
Peter J Krause: Influence Statistics
Concept | World rank |
---|---|
severely immunocompromised hosts | #1 |
adults 31d8 mab | #1 |
people skin biopsies | #1 |
pregnancy neutrophil chemotaxis | #1 |
endorgan dysfunction subjects | #1 |
miyamotoi infection fever | #1 |
consists atovaquone | #1 |
parasitemia organ | #1 |
pneumonia newborn stress | #1 |
rce antimicrobial agents | #1 |
chemotaxis neonates | #1 |
hwa285 mortality | #1 |
local itch response | #1 |
babesiosis immunocompromised | #1 |
balb mice people | #1 |
north america babesia | #1 |
babesia babesia duncani | #1 |
toxins babesiosis | #1 |
pathogen standard | #1 |
motility leukocyte child | #1 |
babesiosis cytapheresis | #1 |
chemotaxis micropore | #1 |
massachusetts diagnosis | #1 |
suspected lifethreatening sepsis | #1 |
serial dilution panels | #1 |
human case babesia | #1 |
choice mildtomoderate illness | #1 |
borrelia miyamotoi response | #1 |
babesia reference strain | #1 |
2 ehrlichial diseases | #1 |
0 2086 units | #1 |
symptomatic powv | #1 |
france humans babesia | #1 |
0 787 units | #1 |
ospa antigen pathogenesis | #1 |
covectored pathogens approach | #1 |
peridomestic nymphal density | #1 |
malignant pertussis apheresis | #1 |
clindamycin quinine | #1 |
coma rare complications | #1 |
6500 unscreened units | #1 |
powv prevalence | #1 |
tickborne pathogen invasion | #1 |
outcomes babesiosis patients | #1 |
cmv antibody prevalence | #1 |
balb tick | #1 |
case babesia | #1 |
Open the FULL List in Excel | |
Prominent publications by Peter J Krause
Borrelia burgdorferi Promotes the Establishment of Babesia microti in the Northeastern United States
[ PUBLICATION ]
Babesia microti and Borrelia burgdorferi, the respective causative agents of human babesiosis and Lyme disease, are maintained in their enzootic cycles by the blacklegged tick (Ixodes scapularis) and use the white-footed mouse (Peromyscus leucopus) as primary reservoir host. The geographic range of both pathogens has expanded in the United States, but the spread of babesiosis has lagged behind that of Lyme disease. Several studies have estimated the basic reproduction number (R0) for B. ...
Known for United States | Babesia Microti | Borrelia Burgdorferi | Lyme Disease | Peromyscus Leucopus |
Quantitative PCR for Detection of Babesia microti in Ixodes scapularis Ticks and in Human Blood
[ PUBLICATION ]
Babesia microti, the primary cause of human babesiosis in the United States, is transmitted by Ixodes scapularis ticks; transmission may also occur through blood transfusion and transplacentally. Most infected people experience a viral-like illness that resolves without complication, but those who are immunocompromised may develop a serious and prolonged illness that is sometimes fatal. The geographic expansion and increasing incidence of human babesiosis in the northeastern and ...
Known for Babesia Microti | Quantitative Pcr | Human Babesiosis | Ixodes Scapularis | United States |
Serologic screening of United States blood donors for Babesia microti using an investigational enzyme immunoassay
[ PUBLICATION ]
BACKGROUND: The tick-borne pathogen Babesia microti has become recognized as the leading infectious risk associated with blood transfusion in the United States, yet no Food and Drug Administration-licensed screening tests are currently available to mitigate this risk. The aim of this study was to evaluate the performance of an investigational enzyme immunoassay (EIA) for B. microti as a screening test applied to endemic and nonendemic blood donor populations.
STUDY DESIGN AND METHODS: ...
Known for United States | Babesia Microti | Blood Donors | New York | Enzyme Immunoassay |
Determination of Babesia microti seroprevalence in blood donor populations using an investigational enzyme immunoassay
[ PUBLICATION ]
BACKGROUND: Transfusion-transmitted babesiosis caused by Babesia microti has emerged as a significant risk to the US blood supply. This study estimated the prevalence of B. microti antibodies in blood donors using an investigational enzyme immunoassay (EIA).
STUDY DESIGN AND METHODS: A peptide-based EIA that detects both immunoglobulin (Ig)G and IgM antibodies to B. microti was developed and validated. Donor samples randomly selected from areas defined as high-risk endemic, lower-risk ...
Known for Babesia Microti | Investigational Enzyme | Blood Donor | Pcr Eia | Transmitted Babesiosis |
Concurrent Lyme Disease and Babesiosis: Evidence for Increased Severity and Duration of Illness
[ PUBLICATION ]
Objective. —To determine whether patients coinfected with Lyme disease and babesiosis in sites where both diseases are zoonotic experience a greater number of symptoms for a longer period of time than those with either infection alone.Design. —Community-based yearly serosurvey and clinic-based cohort study.Setting. —Island community in Rhode Island and 2 Connecticut medical clinics from 1990 to 1994.Study Participants. —Long-term residents of the island community and patients seeking ...
Known for Lyme Disease | Increased Severity | Babesiosis Patients | Duration Symptoms | Rhode Island |
Coevolution of Markers of Innate and Adaptive Immunity in Skin and Peripheral Blood of Patients with Erythema Migrans
[ PUBLICATION ]
We used multiparameter flow cytometry to characterize leukocyte immunophenotypes and cytokines in skin and peripheral blood of patients with erythema migrans (EM). Dermal leukocytes and cytokines were assessed in fluids aspirated from epidermal suction blisters raised over EM lesions and skin of uninfected controls. Compared with corresponding peripheral blood, EM infiltrates were enriched for T cells, monocytes/macrophages, and dendritic cells (DCs), contained lower proportions of ...
Known for Erythema Migrans | Adaptive Immunity | Tolllike Receptor | Peripheral Blood | Cell Surface |
Borrelia miyamotoi is a relapsing fever Borrelia group spirochete that is transmitted by the same hard-bodied (ixodid) tick species that transmit the agents of Lyme disease. It was discovered in 1994 in Ixodes persulcatus ticks in Japan. B. miyamotoi species phylogenetically cluster with the relapsing fever group spirochetes, which usually are transmitted by soft-bodied (argasid) ticks or lice. B. miyamotoi infects at least six Ixodes tick species in North America and Eurasia that ...
Known for Miyamotoi Infection | United States | Relapsing Fever | Tick Species | Lyme Disease |
Human Borrelia miyamotoi infection in California: Serodiagnosis is complicated by multiple endemic Borrelia species
[ PUBLICATION ]
To determine whether human Borrelia miyamotoi infection occurs in the far-western United States, we tested archived sera from northwestern California residents for antibodies to this emerging relapsing fever spirochete. These residents frequently were exposed to I. pacificus ticks in a region where B. miyamotoi tick infection has been reported. We used a two-step B. miyamotoi rGlpQ assay and a B. miyamotoi whole-cell lysate (WCL) assay to detect B. miyamotoi antibody. We also employed ...
Known for Borrelia Miyamotoi | United States | Pacificus Ticks | Infections California | Relapsing Fever |
Emergence of Resistance to Azithromycin-Atovaquone in Immunocompromised Patients with Babesia microti Infection
[ PUBLICATION ]
BACKGROUND: Babesiosis is an emerging tickborne malaria-like infection principally caused by Babesia microti. This infection typically resolves either spontaneously or after administration of a 7-10-day course of azithromycin plus atovaquone or clindamycin plus quinine. Although certain highly immunocompromised patients may respond suboptimally to these drug regimens, unlike the situation with malaria there has been no reported evidence that the cause of treatment failure is infection ...
Known for Babesia Microti | Treatment Babesiosis | Immunocompromised Patients | Atovaquone Azithromycin | Drug Therapy |
BACKGROUND: Babesiosis is a tick-borne, malaria-like illness known to be enzootic in southern New England. A course of clindamycin and quinine is the standard treatment, but this regimen frequently causes adverse reactions and occasionally fails. A promising alternative treatment is atovaquone plus azithromycin.
METHODS: We conducted a prospective, nonblinded, randomized trial of the two regimens in 58 subjects with non-life-threatening babesiosis on Nantucket, on Block Island, and in ...
Known for Clindamycin Quinine | Atovaquone Azithromycin | Treatment Babesiosis | Protozoan Drug Therapy | Southern New England |
OBJECTIVE: A recombinant lipoprotein outer surface protein A (OspA) Lyme disease (LD) vaccine (LYMErix) has been shown to be safe and effective in preventing LD in adults and in adolescents 15 years of age and older. Children are at risk for developing LD. This clinical study was conducted to address the safety and immunogenicity of LD vaccine in children 4 to 18 years of age.
METHODS: A randomized, placebo-controlled clinical trial was conducted at 17 investigational sites in ...
Known for Lyme Disease | Outer Surface | Borrelia Burgdorferi | United States | Bacterial Vaccines |
Evidence-based guidelines for the management of patients with Lyme disease, human granulocytic anaplasmosis (formerly known as human granulocytic ehrlichiosis), and babesiosis were prepared by an expert panel of the Infectious Diseases Society of America. These updated guidelines replace the previous treatment guidelines published in 2000 (Clin Infect Dis 2000; 31[Suppl 1]:1-14). The guidelines are intended for use by health care providers who care for patients who either have these ...
Known for Lyme Disease | Granulocytic Anaplasmosis | Clinical Practice Guidelines | Treatment Prevention | Antimicrobial Therapy |
OBJECTIVE: The objectives of this quality standard are 1) to provide an implementation mechanism that will facilitate the reliable administration of prophylactic antimicrobial agents to patients undergoing operative procedures in which such a practice is judged to be beneficial and 2) to provide a guideline that will help local hospital committees formulate policies and set up mechanisms for their implementation. Although standards in the medical literature spell out recommendations for ...
Known for Surgical Procedures | Antimicrobial Prophylaxis | Prophylactic Antibiotics | Postoperative Infection | Disease Control |
Key People For Lyme Disease
Peter J Krause:Expert Impact
Concepts for whichPeter J Krausehas direct influence:Lyme disease, Babesia microti, Human babesiosis, United states, Quality standard, New england, Borrelia miyamotoi, Miyamotoi infection.
Peter J Krause:KOL impact
Concepts related to the work of other authors for whichfor which Peter J Krause has influence:Lyme disease, Borrelia burgdorferi, Babesia microti, United states, Human babesiosis, Antibiotic prophylaxis, Anaplasma phagocytophilum.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |